IMUX Immunic Inc

EQS-News: Immunic to Participate in Scientific and Investor Conferences in March

Issuer: Immunic AG / Key word(s): Conference
Immunic to Participate in Scientific and Investor Conferences in March

03.03.2025 / 12:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Immunic to Participate in Scientific and Investor Conferences in March
 

NEW YORK, March 3, 2025 –  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March:

  • March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany. The presentations will be accessible on the “Events and Presentations” section of Immunic’s website at: .
  • Title: Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity
  • Presenting Author: Friedrich Hahn, Ph.D., Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
  • Abstract Talk: O 081
  • Session: Antiviral therapy and resistance I
  • Date: March 6, 2025
  • Time: 9:30-9:45 am CET (3:30-3:45am ET)
 
  • Title: Novel Vidofludimus-Based DHODH Inhibitors Containing Carboxylic Acid Bioisosters with Superior Broad-Spectrum Antiviral Activity
  • Presenting Author: Alexandra Herrmann, Ph.D., Manager Translational Pharmacology, Immunic
  • Abstract Talk: O 112
  • Session: Antiviral therapy and resistance II
  • Date: March 7, 2025
  • Time: 11:00-11:15am CET (5:00-5:15am ET)

 

  • March 10-12: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Wednesday, March 12, at 10:00 am ET during this conference in Miami. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: .

Dr. Vitt, Glenn Whaley, Chief Financial Officer, and Jessica Breu, Vice President Investor Relations and Communications, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Leerink representative or Jessica Breu at: .

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: .

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s and employee’s participation in scientific and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, including the ability to satisfy the minimum average price and trading volume conditions required to receive funding in tranche 2 and 3 of the January 2024 private placement, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
09

US IR Contact
Rx Communications Group
Paula Schwartz

US Media Contact
KCSA Strategic Communications
Caitlin Kasunich



Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


fncls.ssp?fn=show_t_gif&application_id=2092003&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
03/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunic Inc

 PRESS RELEASE

EQS-News: Immunic, Inc. to Participate in Scientific and Industry Conf...

Issuer: Immunic AG / Key word(s): Conference Immunic, Inc. to Participate in Scientific and Industry Conferences in April 01.04.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Participate in Scientific and Industry Conferences in April NEW YORK, April 1, 2025 –  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and industry conferences...

 PRESS RELEASE

EQS-News: Immunic to Participate in Scientific and Investor Conference...

Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in March 03.03.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific and Investor Conferences in March   NEW YORK, March 3, 2025 –  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in March:...

 PRESS RELEASE

EQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIM...

Issuer: Immunic AG / Key word(s): Conference/Study Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis 26.02.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement.  Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis – Vidofludimus Calcium’s Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models –  – Top-Line Data...

 PRESS RELEASE

EQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase ...

Issuer: Immunic AG / Key word(s): Study results Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing 20.02.2025 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing  – New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready –  – Dose-Depe...

 PRESS RELEASE

EQS-News: Immunic to Participate in Investor and Scientific Conference...

Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in February 04.02.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement.  Immunic to Participate in Investor and Scientific Conferences in February NEW YORK, February 4, 2025 –  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch